Artivion, Inc. (AORT)

Market Cap	1.07B
Revenue (ttm)	368.21M
Net Income (ttm)	-9.63M
Shares Out	41.73M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	446,167
Open	25.62
Previous Close	25.45
Day's Range	25.17 - 26.26
52-Week Range	12.16 - 26.26
Beta	1.72
Analysts	Strong Buy
Price Target	28.33 (+10.45%)
Earnings Date	Aug 1, 2024

About AORT

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shel...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 1993
• Employees: 1,500
• Stock Exchange: NYSE
• Ticker Symbol: AORT

Financial Performance

In 2023, Artivion's revenue was $354.00 million, an increase of 12.82% compared to the previous year's $313.79 million. Losses were -$30.69 million, 59.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price forecast is $28.33, which is an increase of 10.45% from the latest price.

Price Target

$28.33

(10.45% upside)

Analyst Consensus: Strong Buy